New hope for rare sarcomas: experimental drug QL1706 enters phase 2 trial
NCT ID NCT06939855
First seen Nov 19, 2025 · Last updated Apr 28, 2026 · Updated 14 times
Summary
This study tests an experimental drug called QL1706 in 45 adults with advanced bone or soft tissue sarcoma that cannot be removed by surgery. Participants receive the drug every 3 weeks. The main goal is to see if the drug can stop tumor growth for at least 12 weeks, while also checking for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BONE AND SOFT TISSUE TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.